QBIO News and Press, Q BioMed Inc From 10/03/19

NEW YORK , Oct. 3, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO ), a commercial stage biotech company, announced today it has entered into an exclusive distribution agreement for its non-opioid metastatic cancer pallion drug, Strontium-89 Chloride Injection USP (Strontium-89)/Me...

NEW YORK , Oct. 2, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO),  is pleased to report that it has entered into a settlement agreement with BioNucleonics Inc. to complete the outright acquisition of the non-opioid cancer bone pain drug Strontium-89 Chloride USP. Q BioMed wil...

NEW YORK , Sept. 11, 2019 / PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and Chemveda Life Sciences are very pleased to announce that after the recent successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential chemotherapy for the t...

NEW YORK , Aug. 20, 2019 /PRNewswire/ -- Q BioMed, Inc. (OTCQB: QBIO) and  Chemveda Life Sciences are very pleased to announce the successful chemical synthesis of a unique natural compound that has shown remarkable efficacy as a potential chemotherapy for the treatment of liver c...

Q BioMed ( OTCQB:QBIO ): Q2 GAAP EPS of -$0.20. More news on: Q BioMed Inc., Earnings news and commentary, Tech stocks news, , Read more ...

New York, New York--(Newsfile Corp. - July 11, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, is pleased to announce the latest updates on its non-opioid therapy for the debilitating pain associated with metastatic skeletal cancer. We have been working hard to comm...

Currently no effective treatment exists for the 20,000 children in the U.S. and 250,000 born worldwide each year with pediatric minimally verbal autism (PMVA) New York, New York--(Newsfile Corp. - June 28, 2019) - Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, anno...

New York, New York--(Newsfile Corp. - June 24, 2019) - Q BioMed Inc. (OTCQB: QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. As part of the company's effort to bring awareness to our dev...

No effective treatment exists for the estimated 250,000 children born worldwide each year with pediatric minimally verbal autism (PMVA), of those approximately 20,000 are born in the U.S. Orphan Drug designation application to be filed in June 2019 based on Q BioMed's recent breakth...

NEW YORK , May 30, 2019 /PRNewswire/ --  5W Public Relations , one of the 15 largest independently-owned PR firms in the U.S., is pleased to announce it has been named PR Agency of Record for Q BioMed Inc. (OTCQB: QBIO),  a specialized pharmaceutical accelerator and co...